Achillion Pharma (ACHN) Misses Q4 EPS by 3c
Get Alerts ACHN Hot Sheet
Financial Fact:
Loss from operations: -21.55M
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Achillion Pharma (NASDAQ: ACHN) reported Q4 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).
2015 Financial Guidance
At December 31, 2014, Achillion had cash, cash equivalents, marketable securities and interest and subscription receivables of approximately $159.2 million. Achillion completed a public offering of common stock on February 18, 2015, and received net proceeds of $132.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
The Company expects that research and development expenses during 2015 will be approximately $85 - $95 million and that net cash used in operating activities in 2015 will be approximately $100 - $110 million based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs. The net loss per share is anticipated to approximate $0.95 per share.
For earnings history and earnings-related data on Achillion Pharma (ACHN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Planet Labs (PL) Reports In-Line Q4 EPS, provides guidance
- CVD Equipment (CVV) Reports Q4 Loss of $0.33
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!